Gündüzalp Buğrahan Babacan

Dr. Gündüzalp Buğrahan Babacan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
GBGündüzalp Buğrahan Babacan
Gündüzalp Buğrahan Babacan
MTMerve Nur Acar Tayyar
Merve Nur Acar Tayyar
MŞMehmet Can Şahin
Mehmet Can Şahin
SESelma Şengiz Erhan
Selma Şengiz Erhan
MTMüge Öner Tamam
Müge Öner Tamam
Extranodal lymphomas without lymph node involvement are rarely observed and create diagnostic challenges. We present the case of a 33-year-old woman who was admitted with abdominal swelling. Ultrasonography findings suggested bilateral ovarian masses. 18F-FDG PET/CT revealed intense uptake on the bilateral pelvic mass and thyroid gland. Following excisional surgery and thyroid fine-needle aspiration biopsy, the patient was diagnosed with diffuse large B-cell lymphoma. This case is exceptionally rare, as it presents 2 synchronous extranodal involvements in the ovaries and the thyroid gland independently while not presenting any lymph node activity, which has not been reported before.

1 June 2023 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
SSSeray Saraçoğlu
Seray Saraçoğlu
OGOsman Güven
Osman Güven
GBGündüzalp Buğrahan Babacan
Gündüzalp Buğrahan Babacan
SKSavaş Karyağar
Savaş Karyağar
TÖTamer Özülker
Tamer Özülker
SKSevda Sağlampınar Karyağar
Sevda Sağlampınar Karyağar
The aim of this study was to compare the treatment responses after ablation with 30-50 mCi radioactive iodine (RAI) and 100 mCi RAI in patients with differentiated thyroid cancer (DTC) who were in the low-risk group according to 2015 American Thyroid Associations Classification (ATA 2015) criteria. Between February 2016 and August 2018, 100 patients who received RAI treatment in our clinic after total thyroidectomy and who were in the low-risk group DTC were included in this retrospective study. These patients were divided into 2 groups: low-activity (30-50 mCi) (group 1) and high-activity (100 mCi) (group 2). While 54 patients were treated with low activity, 46 patients received high activity RAI. The 2 groups were compared according to the 1st- and 3rd-year treatment response status. According to the first-year follow-up, 15 patients were accepted as indeterminate response and 85 patients as excellent response. Three (5.5%) of the patients who were accepted as indeterminate response were in group 1 and 12 (26%) were in group 2. According to the third year follow-up, 1 patient in group 1 and 3 patients in group 2 were accepted as indeterminate response. No biochemical incomplete response or recurrent disease was detected. In the chi-square analysis performed to investigate the relationship between the first-year treatment response and RAI activities, a significant relationship was found (p=0.004). In the Mann-Whitney U test performed to investigate the parameters that may be effective in the treatment response, only the preablative serum thyroglobulin value was shown to have a significant difference between the two groups (p=0.01). In the long-term follow-up of the patients, based on the third year treatment response data, chi-square analysis was performed to evaluate the two groups in terms of treatment responses, and no statistically significant relationship was found (p=0.73). Ablation with 30-50 mCi can be safely applied in DTC patients who are in the ATA 2015 low-risk group and are planned for RAI ablation treatment.

26 December 2024 in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Verified
Journal Article
Closed access
MTMerve Nur Acar Tayyar
Merve Nur Acar Tayyar
MTMuge Oner Tamam
Muge Oner Tamam
GBGündüzalp Buğrahan Babacan
Gündüzalp Buğrahan Babacan
MŞMehmet Can Şahin
Mehmet Can Şahin
HOHalim Ozcevik
Halim Ozcevik
KAKadir Atakır
Kadir Atakır

18 February 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
HOHalim Ozcevik
Halim Ozcevik
MTMuge Oner Tamam
Muge Oner Tamam
GBGündüzalp Buğrahan Babacan
Gündüzalp Buğrahan Babacan
SESelma Şengi̇z Erhan
Selma Şengi̇z Erhan
MTMerve Nur Acar Tayyar
Merve Nur Acar Tayyar
BEBi̇rAy Ertürk
Bi̇rAy Ertürk
Background/aim: This study aimed to investigate the relationship between the presence of BRAF, HRAS, NRAS, and KRAS gene mutations and the development of dedifferentiation (iodine-refractory disease) and extrathyroidal disease in patients with differentiated thyroid carcinoma (DTC).Materials and methods: Seventy-seven adult patients classified as intermediate and high-risk according to the ATA 2015 guidelines, who underwent total thyroidectomy followed by radioiodine I-131(RAI) therapy between June 2014 and December 2022, were included. Clinical data were collected via the hospital information system, including the number of surgeries, RAI treatments, and levels of thyroglobulin(Tg), anti-thyroglobulin, and thyroid-stimulating hormone. Histopathological subtypes of DTC were re-evaluated, and mutation analyses of BRAF, KRAS, NRAS, and HRAS genes were performed using real-time polymerase chain reaction (PCR). Statistical analyses were conducted using Medcalc software, with p-values <0.05 considered significant.Results: Of the 77 patients, most had classical papillary thyroid carcinoma, while others represented various subtypes. No mutations were found in BRAF K601E/V600_K601, KRAS G12x-G13D, or NRAS G12-G13; however, NRAS Q61x was found in one patient, HRAS Q61x in 12, and BRAFV600E/Ec in 36. A significant relationship was observed between HRAS Q61x mutation and disease response, alongside a significant association between gene mutations and iodine-refractory disease development (p=0.0004). ROC curve analysis indicated a 49.2 ng/ml threshold for Tg with 75% sensitivity and 94.1% specificity.Conclusion: Our findings suggest that the HRAS Q61x gene mutation is significantly associated with iodine-resistant disease and may serve as a prognostic biomarker in early-stage thyroid cancer and aid in disease monitoring in metastatic patients.

23 January 2024 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
GBGündüzalp Buğrahan Babacan
Gündüzalp Buğrahan Babacan
MTMüge Öner Tamam
Müge Öner Tamam
SESelma Şengiz Erhan
Selma Şengiz Erhan
MŞMehmet Can Şahin
Mehmet Can Şahin
MTMerve Nur Acar Tayyar
Merve Nur Acar Tayyar
A 73-year-old woman with poorly differentiated gastric adenocarcinoma was referred to 18F-FDG PET/CT for evaluation of the disease. FDG PET/CT showed intense uptake in the disseminated lymph nodes. However, there was no uptake in the primary tumoral lesion. Subsequently, 68Ga-FAPI-04 PET/CT was performed with the decision of the tumor board and demonstrated intense uptake in the tumoral lesion. However, there was low or no uptake in disseminated lymph nodes. Tru-cut biopsy results revealed that all the lymph nodes were associated with anthracosis.

5 February 2025 in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Verified
Journal Article
Closed access
GBGündüzalp Buğrahan Babacan
Gündüzalp Buğrahan Babacan
MTMuge Oner Tamam
Muge Oner Tamam
SSS. Saraçoğlu
S. Saraçoğlu
MTM.N. Acar Tayyar
M.N. Acar Tayyar
MŞM.C. Şahin
M.C. Şahin
EÇEmir Çelik
Emir Çelik